Edelfosine nanoemulsions inhibit tumor growth of triple negative breast cancer in zebrafish xenograft model

Abstract Triple negative breast cancer (TNBC) is known for being very aggressive, heterogeneous and highly metastatic. The standard of care treatment is still chemotherapy, with adjacent toxicity and low efficacy, highlighting the need for alternative and more effective therapeutic strategies. Edelf...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sofia M. Saraiva, Carlha Gutiérrez-Lovera, Jeannette Martínez-Val, Sainza Lores, Belén L. Bouzo, Sandra Díez-Villares, Sandra Alijas, Alba Pensado-López, Abi Judit Vázquez-Ríos, Laura Sánchez, María de la Fuente
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/c5de57641ca74482844ef4a0299e782b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c5de57641ca74482844ef4a0299e782b
record_format	dspace
spelling	oai:doaj.org-article:c5de57641ca74482844ef4a0299e782b2021-12-02T14:35:53ZEdelfosine nanoemulsions inhibit tumor growth of triple negative breast cancer in zebrafish xenograft model10.1038/s41598-021-87968-42045-2322https://doaj.org/article/c5de57641ca74482844ef4a0299e782b2021-05-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-87968-4https://doaj.org/toc/2045-2322Abstract Triple negative breast cancer (TNBC) is known for being very aggressive, heterogeneous and highly metastatic. The standard of care treatment is still chemotherapy, with adjacent toxicity and low efficacy, highlighting the need for alternative and more effective therapeutic strategies. Edelfosine, an alkyl-lysophospholipid, has proved to be a promising therapy for several cancer types, upon delivery in lipid nanoparticles. Therefore, the objective of this work was to explore the potential of edelfosine for the treatment of TNBC. Edelfosine nanoemulsions (ET-NEs) composed by edelfosine, Miglyol 812 and phosphatidylcholine as excipients, due to their good safety profile, presented an average size of about 120 nm and a neutral zeta potential, and were stable in biorelevant media. The ability of ET-NEs to interrupt tumor growth in TNBC was demonstrated both in vitro, using a highly aggressive and invasive TNBC cell line, and in vivo, using zebrafish embryos. Importantly, ET-NEs were able to penetrate through the skin barrier of MDA-MB 231 xenografted zebrafish embryos, into the yolk sac, leading to an effective decrease of highly aggressive and invasive tumoral cells’ proliferation. Altogether the results demonstrate the potential of ET-NEs for the development of new therapeutic approaches for TNBC.Sofia M. SaraivaCarlha Gutiérrez-LoveraJeannette Martínez-ValSainza LoresBelén L. BouzoSandra Díez-VillaresSandra AlijasAlba Pensado-LópezAbi Judit Vázquez-RíosLaura SánchezMaría de la FuenteNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-13 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Sofia M. Saraiva Carlha Gutiérrez-Lovera Jeannette Martínez-Val Sainza Lores Belén L. Bouzo Sandra Díez-Villares Sandra Alijas Alba Pensado-López Abi Judit Vázquez-Ríos Laura Sánchez María de la Fuente Edelfosine nanoemulsions inhibit tumor growth of triple negative breast cancer in zebrafish xenograft model
description	Abstract Triple negative breast cancer (TNBC) is known for being very aggressive, heterogeneous and highly metastatic. The standard of care treatment is still chemotherapy, with adjacent toxicity and low efficacy, highlighting the need for alternative and more effective therapeutic strategies. Edelfosine, an alkyl-lysophospholipid, has proved to be a promising therapy for several cancer types, upon delivery in lipid nanoparticles. Therefore, the objective of this work was to explore the potential of edelfosine for the treatment of TNBC. Edelfosine nanoemulsions (ET-NEs) composed by edelfosine, Miglyol 812 and phosphatidylcholine as excipients, due to their good safety profile, presented an average size of about 120 nm and a neutral zeta potential, and were stable in biorelevant media. The ability of ET-NEs to interrupt tumor growth in TNBC was demonstrated both in vitro, using a highly aggressive and invasive TNBC cell line, and in vivo, using zebrafish embryos. Importantly, ET-NEs were able to penetrate through the skin barrier of MDA-MB 231 xenografted zebrafish embryos, into the yolk sac, leading to an effective decrease of highly aggressive and invasive tumoral cells’ proliferation. Altogether the results demonstrate the potential of ET-NEs for the development of new therapeutic approaches for TNBC.
format	article
author	Sofia M. Saraiva Carlha Gutiérrez-Lovera Jeannette Martínez-Val Sainza Lores Belén L. Bouzo Sandra Díez-Villares Sandra Alijas Alba Pensado-López Abi Judit Vázquez-Ríos Laura Sánchez María de la Fuente
author_facet	Sofia M. Saraiva Carlha Gutiérrez-Lovera Jeannette Martínez-Val Sainza Lores Belén L. Bouzo Sandra Díez-Villares Sandra Alijas Alba Pensado-López Abi Judit Vázquez-Ríos Laura Sánchez María de la Fuente
author_sort	Sofia M. Saraiva
title	Edelfosine nanoemulsions inhibit tumor growth of triple negative breast cancer in zebrafish xenograft model
title_short	Edelfosine nanoemulsions inhibit tumor growth of triple negative breast cancer in zebrafish xenograft model
title_full	Edelfosine nanoemulsions inhibit tumor growth of triple negative breast cancer in zebrafish xenograft model
title_fullStr	Edelfosine nanoemulsions inhibit tumor growth of triple negative breast cancer in zebrafish xenograft model
title_full_unstemmed	Edelfosine nanoemulsions inhibit tumor growth of triple negative breast cancer in zebrafish xenograft model
title_sort	edelfosine nanoemulsions inhibit tumor growth of triple negative breast cancer in zebrafish xenograft model
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/c5de57641ca74482844ef4a0299e782b
work_keys_str_mv	AT sofiamsaraiva edelfosinenanoemulsionsinhibittumorgrowthoftriplenegativebreastcancerinzebrafishxenograftmodel AT carlhagutierrezlovera edelfosinenanoemulsionsinhibittumorgrowthoftriplenegativebreastcancerinzebrafishxenograftmodel AT jeannettemartinezval edelfosinenanoemulsionsinhibittumorgrowthoftriplenegativebreastcancerinzebrafishxenograftmodel AT sainzalores edelfosinenanoemulsionsinhibittumorgrowthoftriplenegativebreastcancerinzebrafishxenograftmodel AT belenlbouzo edelfosinenanoemulsionsinhibittumorgrowthoftriplenegativebreastcancerinzebrafishxenograftmodel AT sandradiezvillares edelfosinenanoemulsionsinhibittumorgrowthoftriplenegativebreastcancerinzebrafishxenograftmodel AT sandraalijas edelfosinenanoemulsionsinhibittumorgrowthoftriplenegativebreastcancerinzebrafishxenograftmodel AT albapensadolopez edelfosinenanoemulsionsinhibittumorgrowthoftriplenegativebreastcancerinzebrafishxenograftmodel AT abijuditvazquezrios edelfosinenanoemulsionsinhibittumorgrowthoftriplenegativebreastcancerinzebrafishxenograftmodel AT laurasanchez edelfosinenanoemulsionsinhibittumorgrowthoftriplenegativebreastcancerinzebrafishxenograftmodel AT mariadelafuente edelfosinenanoemulsionsinhibittumorgrowthoftriplenegativebreastcancerinzebrafishxenograftmodel
_version_	1718391034118930432

Edelfosine nanoemulsions inhibit tumor growth of triple negative breast cancer in zebrafish xenograft model

Ejemplares similares